- Home
- SUZ vs PCVX Comparison
SUZ vs PCVX Comparison
Compare SUZ & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUZ
- PCVX
- Stock Information
- Founded
- SUZ 1924
- PCVX 2013
- Country
- SUZ Brazil
- PCVX United States
- Employees
- SUZ N/A
- PCVX N/A
- Industry
- SUZ Paper
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SUZ Basic Materials
- PCVX Health Care
- Exchange
- SUZ Nasdaq
- PCVX Nasdaq
- Market Cap
- SUZ 12.8B
- PCVX 13.2B
- IPO Year
- SUZ N/A
- PCVX 2020
- Fundamental
- Price
- SUZ $9.94
- PCVX $88.71
- Analyst Decision
- SUZ
- PCVX Strong Buy
- Analyst Count
- SUZ 0
- PCVX 7
- Target Price
- SUZ N/A
- PCVX $147.50
- AVG Volume (30 Days)
- SUZ 2.0M
- PCVX 1.1M
- Earning Date
- SUZ 10-24-2024
- PCVX 11-05-2024
- Dividend Yield
- SUZ 2.27%
- PCVX N/A
- EPS Growth
- SUZ N/A
- PCVX N/A
- EPS
- SUZ 0.60
- PCVX N/A
- Revenue
- SUZ $8,006,653,403.00
- PCVX N/A
- Revenue This Year
- SUZ $14.70
- PCVX N/A
- Revenue Next Year
- SUZ $10.62
- PCVX N/A
- P/E Ratio
- SUZ $17.01
- PCVX N/A
- Revenue Growth
- SUZ N/A
- PCVX N/A
- 52 Week Low
- SUZ $8.78
- PCVX $53.83
- 52 Week High
- SUZ $12.98
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SUZ 40.38
- PCVX 41.78
- Support Level
- SUZ $10.28
- PCVX $86.80
- Resistance Level
- SUZ $10.65
- PCVX $92.94
- Average True Range (ATR)
- SUZ 0.20
- PCVX 3.22
- MACD
- SUZ -0.06
- PCVX 0.44
- Stochastic Oscillator
- SUZ 2.11
- PCVX 33.92
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.